AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Merus N.V. (MRUS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

47.61

2.54 (5.64%)

At close: Feb 20, 2025, 3:59 PM

47.63

0.04%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	45.2
Market Cap	3.26B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.03
PE Ratio (ttm)	-11.81
Forward PE	n/a
Analyst	Buy

Ask	49.9
Volume	1,029,958
Avg. Volume (20D)	608,750
Open	45.18
Previous Close	45.07
Day's Range	45.18 - 47.63
52-Week Range	37.77 - 61.61
Beta	undefined

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 19, 2016

Employees 172

Stock Exchange NASDAQ

Ticker Symbol MRUS

Website https://www.merus.nl

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 78.53% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Merus N.V. is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 days ago

+5.15%

Merus shares are trading higher after the company ... Unlock content with Pro Subscription

1 month ago

-7.75%

Merus shares are trading lower. The company announced a research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.

News

1 month ago · seekingalpha.com

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Bizengri's recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab's recent Phase 2 data for HNSCC suggests it could also have b...

2 months ago · benzinga.com

Merus Scores Its First FDA Approval For Lung Cancer Drug

On Wednesday, the FDA approved Merus N.V.'s MRUS Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC...

3 months ago · schaeffersresearch.com

Biotech Stock Boosted on Brand-New 'Buy' Rating

Biotech stock Merus NV (NASDAQ:MRUS) is up 3.4% at $44.40 at last glance, though pulling back a bit from its premarket surge, after Goldman Sachs initiated coverage with a "buy" rating.